In a 195-patient training set derived from the melanoma population of KEYNOTE-001 and using a 1 % cutoff to determine positivity, 71 % of the 125 evaluable patients had PD-L1-positive tumors as assessed using a prototype IHC assay and the 22C3 antibody [35]. This evidence concerns the gene CD274 and melanoma.